[1] 张毅敏,毛彩萍,徐笑红,等. 血清标志物CYFRA21-1、NSE、CEA、CA19-9、CA125、SCC联合检测在肺癌诊断中的应用价值[J]. 中国癌症杂志,2008,18(4):306-309.
[2] 程黎明,邓玲艳,管 青. 评价CYFRA21-1、NSE和CEA对非小细胞肺癌的诊断价值[J]. 中国实验诊断学,2009,13(4):489-492.
[3] 蔡 斌. 人附睾蛋白4在妇科肿瘤诊断及监测中的应用[J]. 实用妇产科杂志,2012,28(1):25-27.
[4] 于 飞,王 倩,钟殿胜,等. 血清人附睾蛋白4检测对肺癌的诊断意义[J]. 天津医药,2014,56(2):116-118.
[5] Hertlein L, Stieber P, Kirschenhofer A, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases[J]. Clin Chem Lab Med, 2012,50(12):2181-2188.
[6] Yamashita S, Tokuishi K, Moroga T, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression[J]. Tumour Biol, 2012,33(6):2365-2370.
[7] Chantapet P, Riantawan P, Lebnak P, et al. Utility of serum cytokeratin 19 fragment(CYFRA 21-1) and carcinaembryonic antigen(CEA) as tumor markers for non-small cell lung cancer[J]. J Med Assoc Thai, 2000, 83(4):383-391.
[8] 蒋长斌,崔邦平,代文莉,等. CEA、NSE及CYFRA21-1联合检测在肺癌诊断与手术治疗中的价值[J]. 重庆医学,2013,42(3):283-284.
[9] Yan HJ, Wang RB, Zhu KL, et al. Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma[J]. Chin Med J (Engl), 2012,125(8):1410-1415.
[10] 周莉莉,高云朝. 尿细胞角蛋白CYFRA 21-1浓度检测对膀胱移行细胞癌的诊断价值[J]. 苏州大学学报: 医学版,2008,28(4):620-621.
[11] 王 英,黄文成,朱 波,等. CYFRA21-1、CA153和TSGF联合检测对乳腺癌诊断的临床意义[J]. 中国现代医学杂志,2006,16(20):3104-3106.
[12] Iwabuchi H, Sakamoto M, Sakunaga H, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors[J]. Cancer Res, 1995,55(24):6172-6180.
[13] Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnositic and prognostic marker for lung cancer[J]. Tumour Biol, 2012,33(4):1141-1149.
[14] Liu W, Yang J, Chi PD, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2013, 17(10):1346-1353.
[15] Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma[J]. Tumour Biol, 2011, 32(2): 265-271. |